These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9859692)

  • 41. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen.
    Evers S; Rahmann A; Kraemer C; Kurlemann G; Debus O; Husstedt IW; Frese A
    Neurology; 2006 Aug; 67(3):497-9. PubMed ID: 16775229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myocardial infarction after taking zolmitriptan.
    Pacheco-Coronado R; McMullan PW; Galbut BH; Galbut EJ; Snell J; Schaer GL; Kavinsky CJ
    Yale J Biol Med; 2005 May; 78(3):147-50. PubMed ID: 16464313
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
    Seaber E; On N; Dixon RM; Gibbens M; Leavens WJ; Liptrot J; Chittick G; Posner J; Rolan PE; Pack RW
    Br J Clin Pharmacol; 1997 Jun; 43(6):579-87. PubMed ID: 9205817
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers.
    Seaber E; On N; Phillips S; Churchus R; Posner J; Rolan P
    Br J Clin Pharmacol; 1996 Feb; 41(2):141-7. PubMed ID: 8838441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers.
    Seaber EJ; Peck RW; Smith DA; Allanson J; Hefting NR; van Lier JJ; Sollie FA; Wemer J; Jonkman JH
    Br J Clin Pharmacol; 1998 Nov; 46(5):433-9. PubMed ID: 9833595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study.
    Visser WH; Klein KB; Cox RC; Jones D; Ferrari MD
    Neurology; 1996 Feb; 46(2):522-6. PubMed ID: 8614525
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).
    Peck RW; Seaber EJ; Dixon R; Gillotin CG; Weatherley BC; Layton G; Posner J
    Br J Clin Pharmacol; 1997 Dec; 44(6):595-9. PubMed ID: 9431839
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The clinical pharmacokinetics of zolmitriptan.
    Dixon R; Warrander A
    Cephalalgia; 1997 Oct; 17 Suppl 18():15-20. PubMed ID: 9399013
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers.
    Dixon RM; Meire HB; Evans DH; Watt H; On N; Posner J; Rolan PE
    Cephalalgia; 1997 Oct; 17(6):639-46. PubMed ID: 9350383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers.
    Mercer AJ; Lamb RJ; Rolan PE; Gibbens M; Posner J
    Psychopharmacology (Berl); 1998 Dec; 140(4):398-404. PubMed ID: 9888613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?
    Goadsby PJ; Hoskin KL
    Pain; 1996 Oct; 67(2-3):355-9. PubMed ID: 8951929
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine.
    Geraud GE
    Eur Neurol; 1996; 36 Suppl 2():24-7. PubMed ID: 8791029
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.
    Smith DA; Cleary EW; Watkins S; Huffman CS; Dilzer SC; Lasseter KC
    J Clin Pharmacol; 1998 Aug; 38(8):685-93. PubMed ID: 9725543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat.
    Goadsby PJ; Knight YE
    Cephalalgia; 1997 May; 17(3):153-8. PubMed ID: 9170337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults.
    Dixon R; Engleman K; Kemp J; Ruckle JL
    J Child Adolesc Psychopharmacol; 1999; 9(1):35-42. PubMed ID: 10357516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine.
    MacLennan SJ; Cambridge D; Whiting MV; Marston C; Martin GR
    Eur J Pharmacol; 1998 Nov; 361(2-3):191-7. PubMed ID: 9865508
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Zolmitriptan. Introduction.
    Mathew N
    Cephalalgia; 1997 Oct; 17 Suppl 18():1-3. PubMed ID: 9399011
    [No Abstract]   [Full Text] [Related]  

  • 58. Low dose zolmitriptan as a 5-HT neuroendocrine challenge agent in humans.
    Moeller FG; Bjork JM; Dougherty DM; Van de Kar LD; Marsh DM; Swann AC
    Psychoneuroendocrinology; 2000 Aug; 25(6):607-18. PubMed ID: 10840172
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 311C90: patient profiles and typical case histories of migraine management.
    Dowson AJ
    Neurology; 1997 Mar; 48(3 Suppl 3):S29-33. PubMed ID: 9071268
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Spinal cord infarction during use of zolmitriptan: a case report.
    Vijayan N; Peacock JH
    Headache; 2000 Jan; 40(1):57-60. PubMed ID: 10759907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.